{"id":3402,"date":"2026-09-23T09:00:00","date_gmt":"2026-09-23T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3402"},"modified":"2026-09-23T20:00:38","modified_gmt":"2026-09-24T00:00:38","slug":"majestec-3-survival-analysis-shows-durable-myeloma-control","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3402","title":{"rendered":"MajesTEC 3 Survival Analysis Shows Durable Myeloma Control"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Johnson & Johnson<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Survival Analysis<\/p>\n

Modality<\/strong><\/p>\n

Bispecific Antibody + CD38 Monoclonal Antibody Combination<\/p>\n

Asset<\/strong><\/p>\n

Teclistamab + Daratumumab<\/p>\n

Target<\/strong><\/p>\n

BCMA \/ CD3 \/ CD38<\/p>\n

Disease Area<\/strong><\/p>\n

Relapsed or Refractory Multiple Myeloma<\/p>\n

Summary<\/h4>\n

Johnson & Johnson released additional analyses of the randomized MajesTEC-3 trial in relapsed or refractory multiple myeloma after one to three prior treatment lines. At 36 months, overall survival was 83.3 percent with teclistamab plus daratumumab versus 65.0 percent with daratumumab-based triplets, with an overall survival hazard ratio of 0.46. A mixture cure model estimated an 86.6 percent statistical cure fraction for the combination. That modeled fraction is a projection, not an observed rate of cured patients.<\/p>\n

The prespecified trial randomized 291 patients to teclistamab plus subcutaneous daratumumab and 296 to daratumumab with pomalidomide or bortezomib and dexamethasone. A post hoc competing-risk analysis reported cumulative progression incidence at 36 months of 8.7 versus 62.1 percent, subdistribution hazard ratio 0.10. Non-relapse mortality was 10.2 versus 9.0 percent, with no statistically significant difference.<\/p>\n

The survival model projected 18.5 remaining years for the experimental arm and 4.9 for control, against 21.1 for an age-matched general population. These lifetime projections extrapolate beyond observed follow-up. The two analyses were announced on 23 September for conference presentation on 23 and 24 September; the later session was a future disclosure at the time of review.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation one is that deep disease control with BCMA-directed T-cell redirection plus CD38 depletion is translating into a real survival advantage. The randomized overall survival comparison and low observed progression incidence support this. Against it, non-relapse mortality remains material and prolonged immune suppression, infection and late relapse require longer observation.<\/p>\n

Interpretation two is that a subset may attain functionally long remission without continuous progression. The long plateau suggested by observed data supports investigation, but mixture cure estimates depend on model choice, follow-up duration, background mortality and later treatments. Control-arm cure estimates were imprecise, with a confidence interval spanning 0 to 53 percent. Calling 87 percent of patients cured would overstate the evidence.<\/p>\n

Upgrade evidence would be stable long-term PFS and OS plateaus, sustained treatment-free remission, mature infection and second-cancer follow-up and external replication. Late relapse or a changing model estimate as the trial matures would falsify the cure interpretation while leaving the observed relative survival benefit intact.<\/p>\n

Company and Product Background<\/h4>\n

Multiple myeloma is a malignant plasma-cell disorder with repeated relapse after sequential treatment. Teclistamab binds CD3 on T cells and BCMA on myeloma cells to recruit immune killing. Daratumumab targets CD38 on malignant plasma cells and modulates the immune environment. The combination is already approved in the United States for specified relapsed disease; the present analysis addresses durability and mechanism of survival benefit rather than a new approval.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Evidence: randomized Phase 3 survival data plus exploratory and post hoc analyses.<\/li>\n
  • Observed three-year OS: 83.3 versus 65.0 percent; HR 0.46.<\/li>\n
  • Modeled statistical cure fraction: 86.6 percent; not observed cure.<\/li>\n
  • Progression incidence: 8.7 versus 62.1 percent at 36 months.<\/li>\n
  • Residual uncertainties: model extrapolation, late toxicity, treatment duration and real-world generalizability.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The new analysis strengthens evidence for sustained myeloma control, but the most dramatic headline is a statistical projection. Inference: the combination may move a subset toward very long remission; whether it produces functional cures cannot be determined from the present follow-up. The observed survival advantage is the defensible signal.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: mixed because randomized survival favors treatment while cure language is unsupported by direct observation. Confidence in Facts: high for reported trial outcomes; moderate for post hoc model outputs as reported. Confidence in Interpretation: moderate-low for projected cure and lifetime survival.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Johnson & Johnson released additional analyses of the randomized MajesTEC-3 trial in relapsed or refractory multiple myeloma after one to three prior treatment lines. At 36 months, overall survival was 83.3 percent with teclistamab…<\/p>\n","protected":false},"author":1,"featured_media":3413,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[824,30,409],"class_list":["post-3402","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-johnson-and-johnson","tag-multiple-myeloma","tag-teclistamab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3402"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3402\/revisions"}],"predecessor-version":[{"id":3418,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3402\/revisions\/3418"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3413"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}